What recession? Pfizer (PFE stock) offers up healthy Q2 on covid drug outperformance


  • Pfizer stock loses ground despite earnings beat.
  • PFE reported an adjusted EPS of $2.04.
  • Covid drugs made up about 60% of its revenue, core company only grew 1%.

Not long after second-quarter US GDP numbers emerged on Thursday morning showing that the US economy is officially in a recession, Pfizer showed it hadn't noticed. The pharmaceutical giant offered up $2.04 in adjusted earnings per share (EPS) that blew past expectations by $0.26. In other words, Pfizer beat analyst consensus by nearly 15%. Revenue then came in at $27.7 billion, which was also well ahead of forecasts by $1.5 billion.

Also readAmazon Stock Deep Dive: AMZN price target at $106 with near-term risks offset by long-term growth

Pfizer stock is surprisingly down after blowing past its Q2 earnings expectations. Shares are off 4.1% to $49.44 in the first 20 minutes of Thursday's regular session. The Federal Reserve reported Q2 GDP that fell 0.9% YoY. Since this is the second consecutive quarter of decline, the US economy is officially in a recession.

Pfizer earnings and outlook: Vaccine provides shot in the arm

Pfizer's coronavirus vaccine Comirnaty and its covid treatment Paxlovid together brought in more than half of the revenue. Comirnaty had sales of $8.85 billion, and Paxlovid nearly matched it with $8.12 billion. This has been the most popular coronavirus vaccine in the world, and Centers for Disease Control estimate 355 million doses of the two-shot vacccine have been administered. For the full year, PFE now estimates it will have sales of $32 billion for Comirnaty and $22 billion for Paxlovid.

Unlike the first quarter, when it beat on adjusted EPS but missed on GAAP EPS, Pfizer reported GAAP EPS for Q2 of $1.73, which was ahead of consensus for $1.64.

The impact of the strong US dollar is very much having a negative impact on the impressive results. Pfizer issued guidance that the lower limit to full-year EPS was being raised by $0.24 and full-year revenue by $2 billion in constant currency terms. When currency fluctuations are taken into account (you know, like in the real world), Pfizer's guidance says full-year revenue will come in $3 billion below consensus and that EPS will only add $0.05 to the prior lower end of guidance (moving from $6.25 to $6.30). 

Besides the currency effect, a major drawback to the earnings was that when covid drugs are taken out of the mix, Pfizer's sales only grew about 1% YoY. Pfizer's JAK inhibitor drug saw sales fall 27% YoY, and its Chantix anti-smoking drug reduced shipments by 99%.

Pfizer stock forecast: Stuck in the middle of pattern

Pfizer stock has been trading inside a symmetrical triangle since February. The apex of the wedge is around $49, so PFE shares have been circling that price all year. To break out of the wedge, PFE stock must close on the weekly chart below above $52.62. The bottom trend line of the wedge structure is at $46.85 at the moment.

The Moving Average Convergence Divergence (MACD) is barely moving. Look for the MACD to wake up before there is any real movement. For now, it looks like Pfizer stock will search for support at the lower trend line near $47.

 

PFE weekly chart

Share: Feed news

Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.

If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.

FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.

The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.

Recommended content


Recommended content

Editors’ Picks

EUR/USD consolidates weekly gains above 1.1150

EUR/USD consolidates weekly gains above 1.1150

EUR/USD moves up and down in a narrow channel slightly above 1.1150 on Friday. In the absence of high-tier macroeconomic data releases, comments from central bank officials and the risk mood could drive the pair's action heading into the weekend.

EUR/USD News
GBP/USD stabilizes near 1.3300, looks to post strong weekly gains

GBP/USD stabilizes near 1.3300, looks to post strong weekly gains

GBP/USD trades modestly higher on the day near 1.3300, supported by the upbeat UK Retail Sales data for August. The pair remains on track to end the week, which featured Fed and BoE policy decisions, with strong gains. 

GBP/USD News
Gold extends rally to new record-high above $2,610

Gold extends rally to new record-high above $2,610

Gold (XAU/USD) preserves its bullish momentum and trades at a new all-time high above $2,610 on Friday. Heightened expectations that global central banks will follow the Fed in easing policy and slashing rates lift XAU/USD.

Gold News
Week ahead – SNB to cut again, RBA to stand pat, PCE inflation also on tap

Week ahead – SNB to cut again, RBA to stand pat, PCE inflation also on tap

SNB is expected to ease for third time; might cut by 50bps. RBA to hold rates but could turn less hawkish as CPI falls. After inaugural Fed cut, attention turns to PCE inflation.

Read more
Bank of Japan set to keep rates on hold after July’s hike shocked markets

Bank of Japan set to keep rates on hold after July’s hike shocked markets

The Bank of Japan is expected to keep its short-term interest rate target between 0.15% and 0.25% on Friday, following the conclusion of its two-day monetary policy review. The decision is set to be announced during the early Asian session. 

Read more
Moneta Markets review 2024: All you need to know

Moneta Markets review 2024: All you need to know

VERIFIED In this review, the FXStreet team provides an independent and thorough analysis based on direct testing and real experiences with Moneta Markets – an excellent broker for novice to intermediate forex traders who want to broaden their knowledge base.

Read More

Forex MAJORS

Cryptocurrencies

Signatures